Recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382 Conditions Adenocarcinoma, Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, +71 more Locations University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States Anchorage Associates in Radiation Medicine — Anchorage, Alaska, United States Anchorage Radiation Therapy Center — Anchorage, Alaska, United States Alaska Breast Care and Surgery LLC — Anchorage, Alaska, United States View all 582 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors NCT07278479 Conditions Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +23 more Locations Emory University Hospital — Atlanta, Georgia, United States United Theranostics — Glen Burnie, Maryland, United States Nebraska Cancer Specialists — Omaha, Nebraska, United States United Theranostics — Princeton, New Jersey, United States View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer NCT03728361 Conditions Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +27 more Locations Ohio State University Comprehensive Cancer Center-COHORT 1 — Columbus, Ohio, United States Ohio State University Comprehensive Cancer Center-COHORT 2 — Columbus, Ohio, United States View Trial Details
